Vifor Pharma AG Logo

Vifor Pharma AG

Global leader in therapies for iron deficiency, anemia, and kidney disease.

VIFN | SW

Overview

Corporate Details

ISIN(s):
CH0364749348
LEI:
529900KO6CN2D9OE1F19
Country:
Switzerland
Address:
Rechenstrasse 37, 9014 St. Gallen

Description

Vifor Pharma AG, now operating as CSL Vifor, is a global pharmaceutical company that develops, manufactures, and markets products for severe and chronic diseases. It is a global leader in therapies for iron deficiency and iron deficiency anemia, with applications in heart failure, kidney disease, gastroenterology, and women's health. The company also has a strong and growing presence in nephrology, aiming to address the full spectrum of kidney disease through its joint company with Fresenius Medical Care Renal Pharma. Vifor Pharma's business model includes strategic global partnering, in-licensing, and the development of innovative therapies to address significant unmet medical needs.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Vifor Pharma AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Vifor Pharma AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Vifor Pharma AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2022-03-09 N/A Executive member Sell None 4,335,210.00 CHF
2022-03-09 N/A Non-Executive member Sell None 1,951,125.00 CHF
2022-03-09 N/A Non-Executive member Sell None 1,851,300.00 CHF
2022-03-09 N/A Executive member Sell None 1,535,160.00 CHF
2022-03-09 N/A Non-Executive member Sell None 1,450,515.00 CHF
2022-03-09 N/A Executive member Sell None 920,205.00 CHF
2022-03-09 N/A Executive member Sell None 530,310.00 CHF
2022-03-09 N/A Non-Executive member Sell None 382,140.00 CHF
2022-03-09 N/A Non-Executive member Sell None 330,495.00 CHF
2022-03-09 N/A Executive member Sell None 287,925.00 CHF

Peer Companies

ELUTIA INC. Logo
Develops drug-eluting biomaterials for medical implants and tissue reconstruction.
United States of America
ELUT
Emergent BioSolutions Inc. Logo
Develops and delivers medical countermeasures for public health threats and crises.
United States of America
EBS
ENANTA PHARMACEUTICALS INC Logo
Biotechnology company developing small molecule drugs for virology and immunology.
United States of America
ENTA
Enervit Logo
Develops sports nutrition, functional foods, and wellness supplements.
Italy
ENV
enGene Holdings Inc. Logo
Clinical-stage biotech developing non-viral gene therapies for local delivery.
United States of America
ENGN
Enliven Therapeutics, Inc. Logo
Clinical-stage biopharma developing kinase inhibitors for precision oncology.
United States of America
ELVN
Enlivex Therapeutics Ltd. Logo
Develops macrophage reprogramming immunotherapy for inflammatory diseases.
United States of America
ENLV
Enlivex Therapeutics Ltd. Logo
A clinical-stage macrophage reprogramming immunotherapy company.
Israel
ENLV
Enorama Pharma AB Logo
Develops and manufactures medicated chewing gums and tobacco-free nicotine pouches.
Sweden
ERMA
Ensol Biosciences Inc. Logo
AI-driven biopharma developing peptide drugs for unmet medical needs.
South Korea
140610

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.